EP4735449A1 - Tetracyclische verbindungen mit einem fusionierten indol zur behandlung von apo1-vermittelter chronischer nierenerkrankung - Google Patents

Tetracyclische verbindungen mit einem fusionierten indol zur behandlung von apo1-vermittelter chronischer nierenerkrankung

Info

Publication number
EP4735449A1
EP4735449A1 EP24832703.3A EP24832703A EP4735449A1 EP 4735449 A1 EP4735449 A1 EP 4735449A1 EP 24832703 A EP24832703 A EP 24832703A EP 4735449 A1 EP4735449 A1 EP 4735449A1
Authority
EP
European Patent Office
Prior art keywords
alkyl
compound
pharmaceutically acceptable
acceptable salt
heterocycloalkyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
EP24832703.3A
Other languages
English (en)
French (fr)
Inventor
Robert Volkmann
Ingrid Mechin
Anil Nair
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
OmniAb Inc
Original Assignee
OmniAb Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by OmniAb Inc filed Critical OmniAb Inc
Publication of EP4735449A1 publication Critical patent/EP4735449A1/de
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/407—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/56—Ring systems containing three or more rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/56—Ring systems containing three or more rings
    • C07D209/80—[b, c]- or [b, d]-condensed
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/56—Ring systems containing three or more rings
    • C07D209/80—[b, c]- or [b, d]-condensed
    • C07D209/94—[b, c]- or [b, d]-condensed containing carbocyclic rings other than six-membered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
    • C07D491/052—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being six-membered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/10—Spiro-condensed systems
    • C07D491/107—Spiro-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Urology & Nephrology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
EP24832703.3A 2023-06-29 2024-06-18 Tetracyclische verbindungen mit einem fusionierten indol zur behandlung von apo1-vermittelter chronischer nierenerkrankung Pending EP4735449A1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202363524176P 2023-06-29 2023-06-29
PCT/US2024/034465 WO2025006262A1 (en) 2023-06-29 2024-06-18 Tetracyclic compounds containing a fused indole for treating apol1-mediated chronic kidney disease

Publications (1)

Publication Number Publication Date
EP4735449A1 true EP4735449A1 (de) 2026-05-06

Family

ID=93939758

Family Applications (1)

Application Number Title Priority Date Filing Date
EP24832703.3A Pending EP4735449A1 (de) 2023-06-29 2024-06-18 Tetracyclische verbindungen mit einem fusionierten indol zur behandlung von apo1-vermittelter chronischer nierenerkrankung

Country Status (2)

Country Link
EP (1) EP4735449A1 (de)
WO (1) WO2025006262A1 (de)

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3714148A (en) * 1968-10-15 1973-01-30 Sumitomo Chemical Co Process for preparing dibenzazocine derivatives and salts thereof
PT1048651E (pt) * 1997-12-03 2003-09-30 Taisho Pharmaceutical Co Ltd Compostos tetraciclicos contendo azoto
JP5031570B2 (ja) * 2004-09-20 2012-09-19 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ 性ステロイドホルモン受容体モジュレーターとして有用な新規な四環式ヘテロ原子含有誘導体
CA2629192A1 (en) * 2005-11-22 2007-05-31 Merck & Co., Inc. Indole orexin receptor antagonists
WO2012040924A1 (en) * 2010-09-29 2012-04-05 Merck Sharp & Dohme Corp. Fused tetracyclic heterocycle compounds and methods of use thereof for treatment of viral diseases
IL283592B2 (en) * 2018-12-17 2025-08-01 Vertex Pharma Inhibitors of apol1 and methods of using same
CN116063223A (zh) * 2022-12-28 2023-05-05 南京林业大学 一种10-全氟烷基-5,10-二氢茚并[1,2-b]吲哚化合物及其合成方法

Also Published As

Publication number Publication date
WO2025006262A1 (en) 2025-01-02

Similar Documents

Publication Publication Date Title
US11655222B2 (en) Certain (2S)-N-[(1S)-1-cyano-2-phenylethyl]-1,4-oxazepane-2-carboxamides as dipeptidyl peptidase 1 inhibitors
EP2809660B1 (de) Makrocyclische verbindungen zur il-17-modulierung
JP6002785B2 (ja) ナトリウムチャネルモジュレーターとしてのベンゾイミダゾールおよびイミダゾピリジン誘導体
US9242964B2 (en) Substituted benzoazepines as toll-like receptor modulators
JP5608217B2 (ja) スルホン酸アミドおよびスルホキシイミン置換ジアリール−シヒドロピリミジノンおよびその使用
US20210246136A1 (en) Cyclobutanes- and azetidine-containing mono and spirocyclic compounds as alpha v integrin inhibitors
KR20230004501A (ko) 안지오텐신 ⅱ와 관련된 질병, 장애, 또는 병태의 치료 및/또는 예방에 유용한 신규 화합물
JP2015527399A (ja) 置換−１，４−ジヒドロピラゾロ［４，３−ｂ］インドール
JP7566745B2 (ja) アルツハイマー病の処置のためのガンマ－セクレターゼモジュレーターとしての、７－フェノキシ－ｎ－（３－アザビシクロ［３．２．１］オクタン－８－イル）－６，７－ジヒドロ－５ｈ－ピロロ［１，２－ｂ］［１，２，４］トリアゾール－２－アミン誘導体及び関連化合物
KR102519948B1 (ko) 암 치료용 화합물 및 조성물
US10583112B2 (en) Benzo[b]furans as bromodomain inhibitors
JP2013177318A (ja) ジヒドロピリミジノン誘導体およびその医薬用途
US11724997B2 (en) Compounds and compositions for treating conditions associated with APJ receptor activity
EP4705296A1 (de) Heteroarylindol-inhibitoren von apol-1
TW202607005A (zh) 用於治療與apj受體活性相關的病狀的化合物及組成物
TW202435883A (zh) １—胺基—４—苯基呔嗪衍生物
KR20190123307A (ko) 브로모도메인 억제제로서의 피라졸 유도체
WO2025006262A1 (en) Tetracyclic compounds containing a fused indole for treating apol1-mediated chronic kidney disease
DK2921489T3 (en) 2-pyridone-RELATED
TW201402569A (zh) 具有ｅｐ１受體活性之經取代的三環化合物（一）
WO2025231011A1 (en) Heteroarylindole inhibitors of apol-1
JPWO2009041475A1 (ja) ピラゾール−３−イル−ベンズアミド誘導体の製造方法
HK40128198A (zh) 用於治疗与apj受体活性有关的疾病的化合物和组合物
CN116925060A (zh) 合成小分子il-17a调节剂的方法
EA049950B1 (ru) Новые соединения, используемые для лечения и/или профилактики заболевания, расстройства или состояния, связанного с ангиотензином ii

Legal Events

Date Code Title Description
STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE

PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE

17P Request for examination filed

Effective date: 20251215

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC ME MK MT NL NO PL PT RO RS SE SI SK SM TR